In this episode, Jillian Moehle focused on the latest evidence-based strategies for recognizing and treating Genitourinary Syndrome of Menopause (GSM). She explored newly updated guidelines from the American Urological Association, emphasizing the importance of proactive screening, a comprehensive approach to patient history, and the range of therapeutic options available, from non-hormonal treatments like moisturizers and lubricants, to hormone-based therapies including low-dose vaginal estrogen. Several points were raised, including safety considerations, the removal of the FDA black box warning on vaginal estrogen, and the crucial role of pelvic floor health in patient outcomes.
Enroll now in: Under-Recognized, Under-Treated, and Misrepresented Realities of the Perimenopause and Menopause Transition, with Leslie Fuller, ND and Jillian Moehle, ND at https://pages.kharrazianinstitute.com/fuller-moehle-perimenopause
00:00 Vaginal treatment recommendations and concerns
05:26 Discussing hormone therapy alternatives
08:13 Treatment options for vaginal health
13:16 FDA removes black box warning
15:24 Support for vaginal estrogen use
18:13 Using GoodRx and applying cream
22:00 Possible side effects and management
24:54 Impact of GSM on women's health
30:59 Podcast outro and resources sharing